Adjuvant postoperative radiotherapy to the cervical lymph nodes in cutaneous melanoma: is there any benefit for high-risk patients?

Author(s): Moncrieff MD, Martin R, O'Brien CJ, Shannon KF, Clark JR, Gao K, McCarthy WM, Thompson JF

Affiliation(s): The Sydney Melanoma Unit, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.

Publication date & source: 2008-11, Ann Surg Oncol., 15(11):3022-7. Epub 2008 Oct 30.

Publication type: Research Support, Non-U.S. Gov't

BACKGROUND: The use of adjuvant radiotherapy after lymph node dissection for metastatic melanoma remains controversial. This study examined the effectiveness of adjuvant radiotherapy in controlling regional disease in high-risk patients. METHODS: A total of 716 patients were identified from a large prospective database who underwent cervical lymph node surgery between 1990 and 2004. Patients with high-risk disease were offered radiotherapy (n = 129), and this group was compared with the group of patients who did not receive radiotherapy (n = 587) in the same period. RESULTS: Radiotherapy did not improve regional control in patients who had metastatic melanoma of the cervical lymph nodes (P = .2). There were 10% fewer regional recurrences in patients with extracapsular spread who received adjuvant radiotherapy, although this was not statistically significant (P = .34). Adjuvant radiotherapy conferred no overall survival benefit to patients with nodal metastases (P = .39). There was a statistically significant trend for worse survival with increasing nodal tumor burden that remained unchanged with adjuvant radiotherapy. CONCLUSION: This large, nonrandomized retrospective study found no evidence to support the use of adjuvant radiotherapy for high-risk melanoma. A multicenter randomized, controlled trial investigating this important clinical dilemma is advocated.